Protein Kinase C α is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells

Breast Cancer Research and Treatment

Volumn 104, Issue 2, 2007, Pages 165-179

  Frankel, Lisa B ^a   Lykkesfeldt, Anne E ^a   Hansen, Jens B ^b   Stenvang, Jan ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Santaris Pharma AS   (Denmark)

Author keywords

Antiestrogen resistance; Breast cancer; ICI 182,780; Locked nucleic acid antisense; Protein kinase C ; Small hairpin RNA; Tamoxifen

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; BIOLOGICAL MARKER; FULVESTRANT; PROTEIN KINASE C ALPHA; SHORT HAIRPIN RNA; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; OLIGONUCLEOTIDES; PROTEIN KINASE C-ALPHA; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 34447519211     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9399-1     Document Type: Article

References (50)

1. Howell SJ, Johnston SR, Howell A (2004) The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 18:47-66
2. Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
3. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-246
4. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M (1995) Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55:3331-3338
5. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C (1989) Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34:123-131
6. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I (2001) HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458
7. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032-1044
8. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE (2005) Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 12:599-614
9. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
10. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824
11. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257:7847-7851
12. Mackay HJ, Twelves CJ (2003) Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 10:389-396
13. O'Brian C, Vogel VG, Singletary SE, Ward NE (1989) Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49:3215-3217
14. Gordge PC, Hulme MJ, Clegg RA, Miller WR (1996) Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer 32A:2120-2126
15. Fabbro D, Kung W, Roos W, Regazzi R, Eppenberger U (1986) Epidermal growth factor binding and protein kinase C activities in human breast cancer cell lines: possible quantitative relationship. Cancer Res 46:2720-2725
16. 2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int J Cancer 40:344-348
17. Newton AC (1995) Protein kinase C: structure, function, and regulation. J Biol Chem 270:28495-28498
18. Michie AM, Nakagawa R (2005) The link between PKCalpha regulation and cellular transformation. Immunol Lett 96:155-162
19. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG (1999) Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 17:3586-3595
20. Roychowdhury D, Lahn M (2003) Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer. Semin Oncol 30:30-33
21. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI (2004) A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100:321-326
22. Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB (2005) Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24:3166-3176
23. Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC (2000) Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 83:782-791
24. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA (2001) Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 7:3156-3165
25. Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA (2006) Overexpression of PKC{alpha} is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 27:1538-1546
26. Briand P, Lykkesfeldt AE (1984) Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res 44:1114-1119
27. Lykkesfeldt AE, Briand P (1986) Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 53:29-35
28. Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54:1587-1595
29. Lykkesfeldt AE, Larsen SS, Briand P (1995) Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61:529-534
30. Fog CK, Christensen IJ, Lykkesfeldt AE (2005) Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668. Breast Cancer Res Treat 91:133-144
31. Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE (1997) Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57:585-589
32. Zeidman R, Lofgren B, Pahlman S, Larsson C (1999) PKCepsilon, via its regulatory domain and independently of its catalytic domain, induces neurite-like processes in neuroblastoma cells. J Cell Biol 145:713-726
33. Trushin SA, Pennington KN, Carmona EM, Asin S, Savoy DN, Billadeau DD, Paya CV (2003) Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes. Mol Cell Biol 23:7068-7081
34. Pagano M, Pepperkok R, Lukas J, Baldin V, Ansorge W, Bartek J, Draetta G (1993) Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol 121:101-111
35. Lundholt BK, Briand P, Lykkesfeldt AE (2001) Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 67:199-214
36. Hansen JB, Westergaard M, Thrue CA, Giwercman B, Oerum H (2003) Antisense knockdown of PKC-alpha using LNA-oligos. Nucleosides Nucleotides Nucleic Acids 22:1607-1609
37. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ (1995) MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95:1906-1915
38. Romanova LY, Alexandrov IA, Nordan RP, Blagosklonny MV, Mushinski JF (1998) Cross-talk between protein kinase C-alpha (PKC-alpha) and -delta (PKC-delta): PKC-alpha elevates the PKC-delta protein level, altering its mRNA transcription and degradation. Biochemistry 37:5558-5565
39. Soh JW, Lee YS, Weinstein IB (2003) Effects of regulatory domains of specific isoforms of protein kinase C on growth control and apoptosis in MCF-7 breast cancer cells. J Exp Ther Oncol 3:115-126
40. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R (1997) MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 57:3486-3493
41. Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF (2005) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104:236-239
42. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249-252
43. Ruvolo PP, Deng X, Carr BK, May WS (1998) A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273:25436-25442
44. Partovian C (2004) Simons M Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal. 16:951-957
45. Fine RL, Patel J, Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85:582-586
46. Gill PK, Gescher A, Gant TW (2001) Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur J Biochem 268:4151-4157
47. de Cremoux P, Tran-Perennou C, Brockdorff BL, Boudou E, Brunner N, Magdelenat H, Lykkesfeldt AE (2003) Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer 10:409-418
48. Keshamouni VG, Mattingly RR, Reddy KB (2002) Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem 277:22558-22565
49. De Servi B, Hermani A, Medunjanin S, Mayer D (2005) Impact of PKCdelta on estrogen receptor localization and activity in breast cancer cells. Oncogene 24:4946-4955
50. Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S (2003) Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer 88:1400-1402